ALTERITY THERAPEUTICS
Alterity Therapeutics has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimerโs, Parkinsonโs and Huntingtonโs diseases.
ALTERITY THERAPEUTICS
Industry:
Biotechnology Chemical Medical
Founded:
1997-01-01
Address:
Parkville, New South Wales, Australia
Country:
Australia
Website Url:
http://www.alteritytherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+61 3 9824 8166
Email Addresses:
[email protected]
Total Funding:
31.4 M USD
Technology used in webpage:
Euro GoDaddy
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2023-12-21 | Alterity Therapeutics appoints Phillip Hains as CFO |
Official Site Inspections
http://www.alteritytherapeutics.com Semrush global rank: 8.83 M Semrush visits lastest month: 459
- Host name: syn05de.syd7.hostyourservices.net
- IP address: 110.232.143.144
- Location: Brisbane Australia
- Latitude: -27.4732
- Longitude: 153.0215
- Timezone: Australia/Brisbane
- Postal: 4000
More informations about "Alterity Therapeutics"
Home - Alterity Therapeutics
Apr 29, 2025 We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. Weโre here to disrupt the trajectory for people living with these debilitating diseases.See details»
About Multiple System Atrophy - Alterity Therapeutics
Alterity Therapeutics - LinkedIn
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases.See details»
Alterity Therapeutics Announces Multiple Oral and Poster
15 hours ago The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support โฆSee details»
Alterity Therapeutics - Crunchbase Company Profile & Funding
ATH434: An oral agent that inhibits the aggregation of proteins such as ฮฑโsynuclein in the central nervous system, currently in Phase 2 clinical trials for Multiple System Atrophy (MSA).See details»
Alterity Therapeutics (ATHE) Company Profile & Description
Apr 29, 2025 Ticker Symbol: ATHE: Exchange: NASDAQ: Fiscal Year: July - June: Reporting Currency: AUD: CIK Code: 0001131343: CUSIP Number: 02155X106: ISIN Number: โฆSee details»
ALTERITY THERAPEUTICS LIMITED - Dun & Bradstreet
Company Description: Prana Biotechnology wants to give Alzheimer's disease a prize fight. The biotechnology company is developing therapies for age-related degenerative conditions, โฆSee details»
Alterity Therapeutics Granted U.S. FDA Fast Track - GlobeNewswire
2 days ago [email protected] +61 3 9349 4906. Ana Luiza Harrop [email protected] +61 452 510 255. U.S. Remy Bernarda โฆSee details»
Alterity Therapeutics
Alterity is dedicated to creating an alternate future for people living with neurodegenerative diseases. Alterity means the state of being different Our goal is to modify the course of diseaseSee details»
Alterity Therapeutics Receives U.S. FDA Approval for โฆ
Sep 20, 2022 For further information please visit the Company's web site at www.alteritytherapeutics.com. Authorisation & Additional information This announcement was โฆSee details»
Alterity Therapeutics - Craft
Oct 28, 2024 Alterity Therapeutics is a company researching and developing therapies to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurodegenerative โฆSee details»
Alterity - 2025 Company Profile & Funding - Tracxn
Apr 27, 2025 Alterity has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Feb 09, 2021 for $495K. 1 investor participated in its latest round, which โฆSee details»
Alterity Therapeutics - Overview, News & Similar companies
Apr 30, 2024 Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE โฆSee details»
Alterity Therapeutics Information - RocketReach
Alteritytherapeutics.com; View Similar People. Related Companies Respiri Limited. 18 $750k Bio-Strategy. 103 $25.5m PolyActiva. 24 $4m Acrux. 98 $90b AusBiotech. 61 $24.7m In Vitro โฆSee details»
The Science - Alterity Therapeutics
REDISTRIBUTE: We know there is excess, loosely bound iron in the brains of patients with MSA. And it is known that this increased iron contributes to the pathology of the disease. ATH434 is โฆSee details»
Alterity Therapeutics Company Overview, Contact Details
Jan 4, 2019 Alterity Therapeutics Ltd. launches Appendix 4C Quarterly Cash Flow Report. MELBOURNE, Australia and SAN FRANCISCO, July 31, 2024 (GLOBE NEWSWIRE) - โฆSee details»
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ...
2 days ago โ Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA โ MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 โฆSee details»
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ...
โ Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA โ MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA โ 5 May โฆSee details»
Alterity Therapeutics Announces Presentation of New Data
Nov 16, 2023 For further information please visit the Companyโs web site at www.alteritytherapeutics.com. Authorisation & Additional information This announcement was โฆSee details»
Alterity Therapeutics - Facebook
Alterity Therapeutics. 169 likes · 10 talking about this. Creating an alternate future for people living with neurodegenerative diseaseSee details»